We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff

By LabMedica International staff writers
Posted on 31 Jul 2024

HORIBA (Kyoto, Japan) is attending this year's ADLM where the company is showcasing its newly launched compact hematology analyzers that offer combined testing for Erythrocyte Sedimentation Rate (ESR) and complete blood count (CBC)/differential (Diff). More...

HORIBA recently expanded its award-winning compact hematology instrument range with the launch of new models with ESR on board. At ADLM 2024, HORIBA is presenting the new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) which now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds.

Visitors to HORIBA’s booth at ADLM 2024 can learn more about the company’s innovative CoRA (Correlated Rouleaux Analysis) technology that has been used to integrate ESR into its three new analyzers. Combining CBC and 5-population white blood cell differential with rapid ESR, calibrated to the Westergren reference method, on one compact analyzer reduces costs per test and turnaround times, and saves laboratory space. Both the Yumizen H550E and H500E models have been further enhanced by offering new connectivity possibilities for data management through HORIBA’s Yumizen P8000 middleware, along with Yumicare. This remote technical support tool enables secure connection to the instrument to monitor workload, reagent consumption, quality control, and instrument alarms.

Also featuring is the new Yumizen C230 benchtop chemistry analyzer for small-volume laboratories with advanced and user-friendly features. This compact integrated solution is designed with system simplicity for efficient performance and processes tests with disposable cuvettes, enabling efficient resource usage. Paired with high-quality POINTE reagents, the new Yumizen C230 provides reliable test results. In addition, HORIBA is showcasing the new Yumizen C240 chemistry analyzer which is designed with system simplicity for expedient and efficient performance. Ideal for mid-sized to small labs, the Yumizen C240 is a compact and cost-efficient analyzer offering full walk-away capabilities and advanced features such as a washing station and pre-warmed detergent water.

Related Links:
HORIBA


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.